$KERX is One to Watch
February 22nd, 2010 at 9:30 am Posted by
As part of Week 10 of The Dean’s free stock picks, The Dean taught the entire student body about Keryx Biopharmaceuticals (NASDAQ: KERX) when it was trading at $2.38 per share. Since then, $KERX has traded as high as $3.20 for a potential profit of 34.45%.
Lately, The Dean’s noticed that $KERX has become quite popular with industry related websites, such as BoardCentral.com, TheStreet.com and Fool.com.
Earlier this month, $KERX reached an agreement with the FDA on the design of a late-stage study of its cancer drug candidate, perifosine (KRX-0401).
Soon after, InvestorSoup.com issued a Biopharmaceutical Stock Alert for $KERX and, that same day, BioMedReports.com reported that $KERX was mentioned in a published article containing an inaccurate statement about the company’s Phase III study.
$KERX CEO Ron Benstur cleared up the specifics of this trial study but this stock has remained the subject of several articles over the past two weeks.
The CollegeStock Community has seen this biopharma move quickly in a short period of time before and The Dean believes $KERX could continue to see attention-worthy volume.
